Selenium 200 mcg for Hashimoto's — The Precise Clinical Dose

Introduction

Selenium is one of the most endocrinologically active trace elements, and the thyroid gland concentrates it more aggressively than any other organ in the human body — more selenium per gram of tissue than the liver, kidneys, or brain (PMID 16164879). This is not incidental: selenium sits at the active center of two enzyme families without which the thyroid cannot function — the iodothyronine deiodinases (D1, D2, D3) and the glutathione peroxidases (GPX1, GPX3).

In the clinic, selenium most often comes up in the context of Hashimoto's autoimmune thyroiditis. Over the last two decades, randomized controlled trials have accumulated that confirm: at the correct dose and form, selenium reduces thyroid peroxidase antibodies (anti-TPO) by 30–40%, reduces the severity of Graves' orbitopathy, and supports remission in postpartum thyroiditis. But all of this works only within a narrow therapeutic window. Dose matters — and a higher dose is not equal to a better effect.

This breakdown answers the central patient question: «How much selenium should I take, and for how long?» — and the central clinician question: «Who actually needs selenium, and for whom is it a useless or harmful supplement?». Grounded in ATA, Endocrine Society, and meta-analyses from 2015–2024.

🌀

Why the thyroid needs selenium: biochemistry

Selenium is incorporated into proteins as selenocysteine — the 21st amino acid, encoded by the stop codon UGA via a special mechanism (the SECIS element in mRNA). In humans, 25 selenoproteins are known; two families are critical for the thyroid.

▸Deiodinases (D1, D2, D3) — enzymes that remove iodine from the thyronine ring. D1 in the liver and kidneys converts T4 → T3 and rT3 → T2. D2 in the pituitary, CNS, and brown fat locally converts T4 → active T3 and maintains feedback with the hypothalamus. D3 is the terminator deiodinase, inactivating T3 to T2 and T4 to inactive rT3. Without selenium these enzymes do not work — the cell remains in functional hypothyroidism despite formally normal T4. ▸Glutathione peroxidases (GPX1, GPX3) — detoxify hydrogen peroxide (H₂O₂) generated in the thyrocyte during thyroid hormone synthesis via thyroid peroxidase. Without GPX, peroxide damages thyrocyte membranes, exposes autoantigens, and triggers an autoimmune cascade. ▸Thioredoxin reductases (TrxR) — maintain redox balance and regenerate vitamin C and other antioxidants.

Normal thyroid selenium concentration is 0.2–0.5 mcg/g wet weight; this is 2–3× higher than in the liver and 10× higher than in skeletal muscle. Evolutionarily this means: the thyroid will not survive without selenium, and during systemic deficiency it claims selenium as a priority, at the expense of peripheral tissues. This is why patients with severe deficiency develop heart and muscle disease first (Keshan cardiomyopathy, Kashin-Beck disease) rather than thyroid disease.

Related: T4 → T3 conversion and the deiodinases — covers how selenium deficiency creates a picture of functional hypothyroidism despite normal T4 and TSH.

🌀

Why 200 mcg specifically: clinical data

The selenium dose is not «more is better». The therapeutic window is narrow, and the optimum has been established in RCTs.

▸< 100 mcg/day — sub-optimal for autoimmune thyroiditis. In the Wichman 2016 meta-analysis (PMID 26396904), doses of 50–80 mcg did not show statistically significant reductions in anti-TPO. ▸150–200 mcg/day — peak anti-TPO suppression. Gärtner (PMID 12390416) in the first large RCT in autoimmune thyroiditis patients showed: 200 mcg selenomethionine for 3 months → 36% reduction in anti-TPO versus placebo. Subsequent RCTs confirmed: 200 mcg × 6 months → 30–40% reduction in anti-TPO. ▸> 400 mcg/day chronically — selenosis. Cumulative: brittle hair and nails, garlic breath, dermatitis, peripheral neuropathy, nausea; in severe cases gastrointestinal disturbance and alopecia. ▸RDA for healthy adults — 55 mcg/day (PMID 12821269). This is the basic daily requirement, not a therapeutic dose.

Important caveat: the «200 mcg optimum» applies to patients with documented autoimmune thyroiditis and low baseline plasma selenium. If plasma selenium is > 120 mcg/L, supplementation is unlikely to deliver an effect because GPX saturation has already been reached. Baseline laboratory assessment — plasma selenium measurement — is therefore critical and is often skipped in practice.

Geography matters in parallel: in regions with selenium-poor soil (Finland, parts of Eastern Europe, northern Russia and Ukraine) baseline status is lower and the supplementation effect is more pronounced. In regions with selenium-rich soil (most US states) routine intake is not justified.

🌀

Form matters

Selenium bioavailability varies tenfold depending on chemical form.

▸L-selenomethionine — organic form, the most extensively studied in RCTs for autoimmune thyroiditis. Bioavailability ~90%. Incorporated into body proteins in place of methionine, building a tissue depot — critical for long-term support. ▸Selenium-enriched yeast — natural organic form, predominantly L-selenomethionine plus small amounts of selenocysteine. Well tolerated, suitable for baseline repletion. ▸Sodium selenite (Na₂SeO₃) and sodium selenate (Na₂SeO₄) — inorganic forms. Bioavailability 20–50%. Less tissue accumulation, faster clearance. Not recommended for long-term use in autoimmune thyroiditis. Used historically in Marcocci RCT for Graves' orbitopathy (PMID 21507197) at 200 mcg/day × 6 months — it worked there, but that is a short course for a specific indication. ▸Methylselenocysteine (Se-methylselenocysteine) — a relatively new form with cancer-prevention interest, but clinically unproven in autoimmune thyroiditis. Not first-line.

Practical conclusion: for Hashimoto's, choose L-selenomethionine 200 mcg in capsule form. This is the standard on which the evidence base is built. Sodium selenite from yesterday's multivitamin tablet does not work for autoimmune thyroiditis as a standalone intervention.

🌀

When selenium works: indications

Selenium is not a general «thyroid supplement». It is a targeted cofactor with specific indications.

▸Hashimoto's autoimmune thyroiditis with anti-TPO > 100 IU/mL — the primary indication. Goal: reduce autoimmune activity. Maximal effect at 6 months. ▸Postpartum thyroiditis — selenium supports remission and reduces transition to chronic autoimmune thyroiditis. Course 6–12 months. ▸Graves' disease with mild active orbitopathy — Marcocci et al. (PMID 21507197) showed: selenium 200 mcg/day × 6 months slows progression of mild to moderate orbitopathy and improves quality of life. Recommended by EUGOGO/ETA for mild active orbitopathy within the first 6 months (PMID 34297690). ▸Subacute thyroiditis (de Quervain) — supports thyrocyte recovery during the resolution phase. Course 3 months. ▸Laboratory-verified selenium deficiency (plasma < 80 mcg/L) — independent of thyroid status. Replete to the target 120–150 mcg/L.

All these scenarios share something in common — either documented autoimmune activity or confirmed deficiency. Without either, there is no target.

🌀

When selenium is useless or harmful

More often than it should be, selenium is prescribed «just in case» — and this is wrong.

▸Normal anti-TPO + normal TSH — a healthy thyroid does not need supplemental selenium beyond dietary intake. Supplementation provides no preventive benefit. ▸Plasma selenium > 120 mcg/L — GPX saturation is already achieved; additional selenium does not increase enzyme activity but raises selenosis risk with prolonged use. ▸Non-toxic nodular goiter without autoimmune thyroiditis — pathogenesis is not selenium-dependent; supplementation has no effect. ▸Isolated iodine deficiency — the thyroid needs iodine, not selenium. Selenium given to an iodine-deficient patient may worsen the picture: D2 without T4 substrate cannot make T3. Replete iodine first (see the five-step iodine protocol). ▸Active hyperthyroidism without orbitopathy — no evidence of benefit in isolated thyrotoxicosis without autoimmune eye involvement. ▸Chronic continuous use > 1 year without reassessment — selenosis risk. ▸Pregnancy at doses > 200 mcg/day — data are limited; routinely do not exceed the RDA for pregnancy (60 mcg/day).

This article is not a license for patients to buy selenium at the pharmacy. It is a clinician's tool: indicated or not, and if indicated — at what dose and for how long.

🌀

Full panel: protocol

Before starting selenium for suspected autoimmune thyroiditis — an extended panel:

▸TSH, free T4, free T3, reverse T3 — functional thyroid status ▸Anti-TPO, anti-Tg — autoimmune status ▸Thyroid ultrasound — structural assessment, diffuse changes, nodules ▸Plasma (or whole blood) selenium — baseline status. Target range 120–150 mcg/L. ▸Erythrocyte glutathione peroxidase (GPx1) — functional selenium marker, reflects depot over the last 120 days (erythrocyte lifespan). ▸Urinary iodine (spot or 24-hour) — parallel iodine status assessment, since selenium and iodine work as a pair. ▸Ferritin, vitamin D, B12, zinc — thyroid function cofactors whose deficiencies mask the selenium effect.

Standard protocol for confirmed autoimmune thyroiditis with anti-TPO > 100 IU/mL and baseline selenium < 120 mcg/L:

▸L-selenomethionine 200 mcg/day in the morning, fasting or with a light breakfast ▸Course duration 6 months continuous ▸1-month pause to assess independent dynamics and prevent accumulation ▸Repeat course as indicated — if anti-TPO rises again, plasma selenium falls below 120 mcg/L, or autoimmune activity persists ▸Vitamin D > 50 ng/mL in parallel — synergistic immunomodulatory effect ▸Zinc 15–25 mg/day — thyroid function and immunity cofactor

Alternative protocol for Graves' orbitopathy: sodium selenite or L-selenomethionine 100 mcg twice daily × 6 months per the EUGOGO/Marcocci protocol.

🌀

Monitoring and control

Without monitoring, therapy becomes guesswork. Minimum monitoring protocol:

▸Plasma selenium — at baseline and at 3 months. Target 120–150 mcg/L. If not reached at 3 months, continue; if exceeded, reduce to 100 mcg/day or switch to maintenance. ▸Erythrocyte glutathione peroxidase (GPx1) — functional saturation marker. At baseline and at 3–6 months. A plateau in GPx1 activity signals that further selenium increase will not add functional benefit. ▸Anti-TPO, anti-Tg — at 6 months. A reduction of 25% or more is a clinically meaningful response. A reduction of less than 15% — reconsider strategy (check iodine status, screen for concurrent autoimmune disease, evaluate the role of low-dose naltrexone). ▸TSH, free T3, free T4 — at 3 and 6 months. Goal — stable or improving function. ▸Complete blood count, liver enzymes (ALT, AST) — every 6 months on prolonged therapy. Selenium is metabolized in the liver. ▸Selenosis symptoms — interview at every visit: brittle hair and nails, garlic breath, dermatitis, paresthesia. If present — reconsider the dose.

If after 6 months anti-TPO has not changed or is rising, selenium has not worked in isolation. In this scenario consider low-dose naltrexone (LDN), cortisol and HPA axis correction, evaluation of autoimmune triggers (EBV, intestinal permeability, vitamin D deficiency).

🌀

Food sources

Dietary selenium is the baseline. In a patient with a varied diet, deficiency is uncommon. Top sources:

▸Brazil nut — 1 nut = 70–90 mcg selenium. Important caveat: selenium concentration in nuts varies widely by growing region (8–130 mcg/nut). Daily consumption of 3–4 nuts can produce selenosis. ▸Tuna (fresh or canned) — 100 g = 80–90 mcg ▸Sardine — 100 g = 45–55 mcg ▸Shrimp, squid — 100 g = 35–45 mcg ▸Egg — 1 egg = 15 mcg ▸Sunflower seeds — 30 g = 23 mcg ▸Chicken breast — 100 g = 22 mcg ▸Beef — 100 g = 18 mcg ▸Whole-grain bread, oatmeal — 100 g = 10–15 mcg (region-dependent)

For a healthy adult consuming fish twice weekly and eggs daily, the basic 55 mcg/day requirement is covered by diet. On a vegetarian or vegan diet with minimal nuts and seeds, plasma selenium often runs at the lower end of normal, and in the presence of autoimmune thyroiditis it makes sense to check status and consider targeted supplementation.

Related: iodine and the thyroid — covers the parallel cofactor without which selenium cannot realize its effect.

🌀

Caution: limitations

Selenium is a pharmacologically active trace element, not a «safe supplement». Limitations and interactions:

▸Selenosis at > 400 mcg/day chronically — brittle hair and nails, garlic breath (dimethylselenide in exhaled air), peripheral neuropathy, dermatitis, nausea, gastrointestinal disturbance. On appearance — stop immediately; plasma selenium normalizes over 1–3 months. ▸Pregnancy — routinely do not exceed 60 mcg/day (RDA for pregnancy). Data on 200 mcg during pregnancy are limited and inconsistent. ▸Antithyroid drugs (methimazole, propylthiouracil) — selenium may slightly amplify the effect. In hyperthyroidism on therapy — monitor TSH and free T4 more frequently. ▸L-thyroxine and Thyroid-S (NDT) — selenium may alter T4 → T3 conversion by normalizing D2 activity. With long courses and dynamic anti-TPO, replacement therapy dose may need adjustment. Check TSH and free T3 at 3 months. ▸Anticoagulants (warfarin, apixaban) — high selenium doses potentially affect platelet aggregation. Clinically significant rarely, but on prolonged therapy — monitor. ▸Chemotherapy — selenium can interact with cisplatin, ifosfamide, and other cytotoxic agents. Only with oncologist coordination. ▸ATA and Endocrine Society — as of 2024 do not recommend routine selenium as first-line standard of care for autoimmune thyroiditis. Clinical outcome data (progression to overt hypothyroidism) are heterogeneous (Wichman 2016, PMID 26396904). This means: selenium is a reasonable intervention in correctly selected patients but not universal.

🌀

Bottom line

Selenium is a targeted cofactor, not a panacea. The 200 mcg × 6 months dose is justified in confirmed autoimmune thyroiditis with anti-TPO above 100 IU/mL and low baseline selenium status. A smaller dose produces no clinically meaningful effect; a larger one accumulates and is toxic. Form — L-selenomethionine, not inorganic selenite. Monitoring — plasma selenium, erythrocyte glutathione peroxidase, anti-TPO every 6 months.

Selenium does not replace iodine, vitamin D, zinc, or the basic management of autoimmune thyroiditis. It is part of a holistic protocol, not its center. Prescribing «just in case» leads to selenosis. Prescribing on clear indications leads to reduced autoimmune activity and stable thyroid function for years.

🌀

About the author

I am Dr. Vladimir Pereligyn, endocrinologist and researcher. I specialize in endocrine, metabolic, and autoimmune protocols with a holistic approach and individualized lab diagnostics. Book a consultation — universum.earth/consultation. Daily clinical breakdowns — @md_pereligyn_thyroid.

🌀

Sources

▸Köhrle J. Selenium and the thyroid. *Curr Opin Endocrinol Diabetes Obes.* 2015 (PMID 16164879) — selenium biochemistry in the thyrocyte, deiodinases. ▸Gärtner R, Gasnier BCH. Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. *J Clin Endocrinol Metab.* 2002 (PMID 12390416) — first large RCT, 200 mcg selenomethionine 3 months, 36% anti-TPO reduction. ▸Marcocci C, et al. Selenium and the course of mild Graves' orbitopathy. *N Engl J Med.* 2011 (PMID 21507197) — RCT, sodium selenite 200 mcg/day × 6 months in mild Graves' orbitopathy. ▸Tinggi U. Selenium: its role as antioxidant in human health. *Environ Health Prev Med.* 2008 (PMID 12821269) — review of bioavailability, RDA, selenium toxicity. ▸Wichman J, et al. Selenium supplementation significantly reduces thyroid autoantibody levels in patients with chronic autoimmune thyroiditis: a systematic review and meta-analysis. *Thyroid.* 2016 (PMID 26396904) — meta-analysis of RCTs, anti-TPO reduction confirmed, caveat on clinical outcomes. ▸Toulis KA, et al. Selenium supplementation in the treatment of Hashimoto's thyroiditis: a systematic review and a meta-analysis. *Thyroid.* 2010 (PMID 20578897) — meta-analysis, efficacy of selenomethionine in autoimmune thyroiditis. ▸Bartalena L, et al. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. *Eur J Endocrinol.* 2021 (PMID 34297690) — ETA selenium recommendations in Graves' orbitopathy.

*This article is for informational purposes only and does not replace a medical consultation. Before starting any supplements, changing medication, or undergoing diagnostic procedures, discuss the plan with your physician.*